HC Wainwright Issues Positive Estimate for ETON Earnings

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – Investment analysts at HC Wainwright lifted their Q2 2025 earnings estimates for Eton Pharmaceuticals in a report released on Thursday, January 23rd. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of $0.17 for the quarter, up from their previous forecast of $0.08. HC Wainwright currently has a “Buy” rating and a $33.00 price objective on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.14) per share. HC Wainwright also issued estimates for Eton Pharmaceuticals’ Q3 2025 earnings at $0.26 EPS, Q4 2025 earnings at $0.34 EPS, FY2025 earnings at $0.81 EPS, FY2026 earnings at $2.01 EPS, FY2027 earnings at $2.63 EPS, FY2028 earnings at $3.82 EPS and FY2029 earnings at $4.89 EPS.

A number of other analysts have also issued reports on the company. Craig Hallum increased their target price on Eton Pharmaceuticals from $15.00 to $18.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. B. Riley initiated coverage on Eton Pharmaceuticals in a research note on Friday, January 10th. They issued a “buy” rating and a $21.00 price objective for the company.

Eton Pharmaceuticals Stock Performance

Shares of NASDAQ:ETON opened at $17.64 on Monday. The firm has a 50 day simple moving average of $13.11 and a 200 day simple moving average of $8.47. Eton Pharmaceuticals has a 52 week low of $3.03 and a 52 week high of $17.76. The company has a market cap of $459.52 million, a PE ratio of -80.18 and a beta of 1.38.

Institutional Trading of Eton Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of ETON. Point72 Asia Singapore Pte. Ltd. acquired a new position in Eton Pharmaceuticals in the 3rd quarter worth about $54,000. Jane Street Group LLC bought a new position in Eton Pharmaceuticals during the third quarter valued at approximately $90,000. Renaissance Technologies LLC raised its position in Eton Pharmaceuticals by 63.8% during the second quarter. Renaissance Technologies LLC now owns 106,500 shares of the company’s stock valued at $350,000 after acquiring an additional 41,469 shares in the last quarter. Stonepine Capital Management LLC bought a new stake in Eton Pharmaceuticals in the second quarter worth approximately $362,000. Finally, Baader Bank Aktiengesellschaft bought a new stake in Eton Pharmaceuticals in the fourth quarter worth approximately $373,000. 27.86% of the stock is currently owned by hedge funds and other institutional investors.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.